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Levetiracetam enhances the Temozolomide effect on 
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Glioblastoma Multiforme (GBM) is a highly aggressive brain tumor in which can-
cer cells with stem cell-like features, called Cancer Stem Cells (CSCs), were identi-
fied. CSCs show a high capacity to resist to standard therapies, finally leading to a 
poor prognosis. Thus, the development of efficient strategies targeting these cells are 
urgently needed. We have previously demonstrated the presence of two CSC popula-
tions in GBM, one derived from the GBM area called enhanced lesion (GCSC) and 
the other one from the brain area adjacent to the tumor margin (PCSC), that greatly 
differ in their growth properties and tumor-initiating ability. Tumor recurrence occurs 
in tissue neighboring GBM suggesting a growing relevance for this area in transla-
tional research. To date the most effective chemotherapies to treat GBM are alkylating 
agents such as temozolomide (TMZ). Epigenetic mechanisms are increasingly recog-
nized as a major factor contributing to pathogenesis of cancer including glioblastoma. 
Histone deacetylase (HDAC) inhibitors can interfere with TMZ activity by modulat-
ing methylguanine methyltransferase (MGMT) expression, resulting in increased 
TMZ efficacy. Levetiracetam (LEV), an antiepileptic drug, is known to modulate the 
transcription of HDAC, ultimately silencing MGMT.Since TMZ is the chemothera-
peutic agent most widely used in newly diagnosed adult glioblastoma patients, we 
evaluated its effects on the proliferation rate of both GCSC and PCSC deriving from 
five patients, in comparison with the effects of other drugs such as etoposide, irinote-
can and car-boplatin. Our results demonstrated that TMZ was the less efficient agent, 
hence we verified the pos-sibility to increase the effect of TMZ by combining it with 
LEV. Here we show that LEV signifi-cantly enhances the inhibitory effect of TMZ on 
the proliferation of the GCSC deriving from four patients and of the PCSC deriving 
from two patients. This effect seems to be mediated by HDAC6 since its expression is 
up-regulated in the TMZ resistant cells and correlates with MGMT expression. Taken 
together our results suggest that GCSC and PCSC differ in their ability to respond 
to the combined chemotherapeutic treatment we used and that the manipulation of 
HDAC6 expression might be a potential strategy for treating glioblastoma and over-
coming resistance to TMZ.
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